Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Valencak
J
J
Raderer
M
M
Kornek
G V
GV
Henja
M H
MH
Scheithauer
W
W
D015746:Abdominal Pain / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001285:Atropine / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002799:Cholinergic Fibers / Q000187:drug effects*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010276:Parasympatholytics / Q000627:therapeutic use; D012472:Salivation / Q000187:drug effects; D059004:Topoisomerase I Inhibitors
D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D010276:Parasympatholytics; D059004:Topoisomerase I Inhibitors; D000077150:Oxaliplatin; D000077146:Irinotecan; D001285:Atropine; D002166:Camptothecin